Flamel Tech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Avadel Pharmaceuticals PLC (AVDL)
Avadel Pharmaceuticals PLC stock price live, this page displays NASDAQ AVDL stock exchange data. View the AVDL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Avadel Pharmaceuticals PLC real time stock price chart below.
What Is the Avadel Pharmaceuticals PLC Stock Price Today?
The Avadel Pharmaceuticals PLC stock price today is 13.690.
What Is the Stock Symbol for Avadel Pharmaceuticals PLC?
The stock symbol for Avadel Pharmaceuticals PLC is ""AVDL.""
What Stock Exchange Does Avadel Pharmaceuticals PLC Trade On?
Avadel Pharmaceuticals PLC is listed and trades on the NASDAQ stock exchange.
Is Avadel Pharmaceuticals PLC a Good Stock to Buy?
Determining whether Avadel Pharmaceuticals PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVDL quote. (ISIN: IE00BDGMC594)
What Is the Avadel Pharmaceuticals PLC Stock Price Today?
The Avadel Pharmaceuticals PLC stock price today is 13.690.
What Is the Stock Symbol for Avadel Pharmaceuticals PLC?
The stock symbol for Avadel Pharmaceuticals PLC is ""AVDL.""
What Stock Exchange Does Avadel Pharmaceuticals PLC Trade On?
Avadel Pharmaceuticals PLC is listed and trades on the NASDAQ stock exchange.
Is Avadel Pharmaceuticals PLC a Good Stock to Buy?
Determining whether Avadel Pharmaceuticals PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVDL quote. (ISIN: IE00BDGMC594)
NASDAQ
Currency in USD
Fair Value
An estimate of a Avadel Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.380
13.830
52 wk Range
6.380
16.660
AVDL Scorecard
Full Analysis
Net income is expected to grow this year
AVDL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Avadel Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.38013.830
52 wk Range
6.38016.660
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AVDL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Avadel Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
18.250
Upside
+33.31%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Avadel Pharmaceuticals PLC Company Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Avadel Pharmaceuticals PLC Earnings Call Summary for Q4/2024
- Q4 2024 revenue of $50.41M missed forecast; EPS of -$0.05 below expectations due to inventory channel changes
- Stock rose 4.05% to $8.23 post-earnings; company maintains 91.92% gross profit margin and $73M cash balance
- LumRise narcolepsy treatment shows strong market penetration with nearly $200M in net sales
- 2025 revenue guidance of $240-260M, targeting 50% YoY growth and $1B market opportunity in narcolepsy
- CEO emphasizes 2025 as growth year; CFO notes forecast conservatism amid expansion plans and market challenges
Last Updated: 03/03/2025, 15:36
Read Full TranscriptCompare AVDL to Peers and Sector
Metrics to compare | AVDL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVDLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −454.8x | −3.1x | −0.5x | |
PEG Ratio | −4.67 | 0.00 | 0.00 | |
Price/Book | 14.7x | 2.9x | 2.6x | |
Price / LTM Sales | 6.0x | 1.7x | 3.3x | |
Upside (Analyst Target) | 31.5% | 67.5% | 40.1% | |
Fair Value Upside | Unlock | 12.5% | 5.1% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 18.250
(+33.31% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
0.10 / 0.03
Revenue / Forecast
68.13M / 61.40M
People Also Watch
FAQ
What Stock Exchange Does Avadel Pharma Trade On?
Avadel Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Avadel Pharma?
The stock symbol for Avadel Pharma is "AVDL."
What Is the Avadel Pharma Market Cap?
As of today, Avadel Pharma market cap is 1.33B.
What Is Avadel Pharma's Earnings Per Share (TTM)?
The Avadel Pharma EPS (TTM) is -0.03.
When Is the Next Avadel Pharma Earnings Date?
Avadel Pharma will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is AVDL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Avadel Pharma Stock Split?
Avadel Pharma has split 0 times.
How Many Employees Does Avadel Pharma Have?
Avadel Pharma has 188 employees.
What is the current trading status of Avadel Pharma (AVDL)?
As of 17 Aug 2025, Avadel Pharma (AVDL) is trading at a price of 13.69, with a previous close of 13.50. The stock has fluctuated within a day range of 13.38 to 13.83, while its 52-week range spans from 6.38 to 16.66.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.